ArticleEuropean heart journal2016
Troponin I and cardiovascular risk prediction in the general population: the BiomarCaRE consortium.
Article in European heart journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
103 citing papers in PubMed, 5 syntheses or guidelines pooled it, 268 citations in OpenAlex.
- Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-Analysis.Journal of the American College of Cardiology · 2025 · on this mapPooled it
- Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.The New England journal of medicine · 2023Pooled it
- A Systematic Review and Meta-Analysis of Advanced Biomarkers for Predicting Incident Cardiovascular Disease among Asymptomatic Middle-Aged Adults.International journal of molecular sciences · 2022Pooled it
- High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants.Journal of the American College of Cardiology · 2017Pooled it
- Prognostic value of basal high-sensitive cardiac troponin levels on mortality in the general population: A meta-analysis.Medicine · 2016Pooled it
- Impact of subthreshold troponin levels and temporal trends on short term adverse cardiovascular outcomes in patients discharged from the emergency department: a RACE-IT trial substudy.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Trial
- Effects of diltiazem and metoprolol on levels of high-sensitivity troponin I in patients with permanent atrial fibrillation: a randomized trial.BMC cardiovascular disorders · 2025Trial
- Aggregate Clinical and Biomarker-Based Model Predicts Adverse Outcomes in Patients With Coronary Artery Disease.The American journal of cardiology · 2023Trial
- Factors associated with baseline and serial changes in circulating NT-proBNP and high-sensitivity cardiac troponin T in a population-based cohort (Dallas Heart Study).Biomarkers in medicine · 2021Trial
- Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines.JAMA cardiology · 2020 · on this mapTrial
- Markers of Myocardial Stress, Myocardial Injury, and Subclinical Inflammation and the Risk of Sudden Death.Circulation · 2020Trial
- High-sensitivity cardiac troponin I and risk of heart failure in patients with suspected acute coronary syndrome: a cohort study.European heart journal. Quality of care & clinical outcomes · 2018Trial
- Cardiovascular risk stratification in obstructive sleep apnea: a potential role for cardiac troponins.Sleep · 2026Article
- Clinical Significance of High-Sensitivity Cardiac Troponin I and Myoglobin in Patients with Suspected Coronary Microvascular Dysfunction.Journal of cardiovascular translational research · 2026Article
- High-Sensitivity Cardiac Troponin I in Apparently Healthy Blood Donors: Cross-Sectional Distribution and Discordance with Conventional Cardiovascular Risk Assessment Methods.Diagnostics (Basel, Switzerland) · 2026Article
- Correcting Measurement Error and Zero Inflation in Functional Covariates for Scalar-on-Function Quantile Regression.Statistics in medicine · 2026Article
- High-sensitivity cardiac troponin I and risk of dementia: the 25-year longitudinal Whitehall II study.European heart journal · 2026Article
- Article
- High sensitivity troponin-I and myocardial injury after noncardiac surgery for cancer in a large prospective cohort.BMC anesthesiology · 2025Article
- 99th-Percentile Upper Reference Limit for the New Snibe High-Sensitivity Troponin I Assay in a Southeast Asian Population.Diagnostics (Basel, Switzerland) · 2025Article
43 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
28 authors at 13 institutions in 6 countries.
Funding
Abstract
aimsOur aims were to evaluate the distribution of troponin I concentrations in population cohorts across Europe, to characterize the association with cardiovascular outcomes, to determine the predictive value beyond the variables used in the ESC SCORE, to test a potentially clinically relevant cut-off value, and to evaluate the improved eligibility for statin therapy based on elevated troponin I concentrations retrospectively. METHODS AND
resultsBased on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE) project, we analysed individual level data from 10 prospective population-based studies including 74 738 participants. We investigated the value of adding troponin I levels to conventional risk factors for prediction of cardiovascular disease by calculating measures of discrimination (C-index) and net reclassification improvement (NRI). We further tested the clinical implication of statin therapy based on troponin concentration in 12 956 individuals free of cardiovascular disease in the JUPITER study. Troponin I remained an independent predictor with a hazard ratio of 1.37 for cardiovascular mortality, 1.23 for cardiovascular disease, and 1.24 for total mortality. The addition of troponin I information to a prognostic model for cardiovascular death constructed of ESC SCORE variables increased the C-index discrimination measure by 0.007 and yielded an NRI of 0.048, whereas the addition to prognostic models for cardiovascular disease and total mortality led to lesser C-index discrimination and NRI increment. In individuals above 6 ng/L of troponin I, a concentration near the upper quintile in BiomarCaRE (5.9 ng/L) and JUPITER (5.8 ng/L), rosuvastatin therapy resulted in higher absolute risk reduction compared with individuals <6 ng/L of troponin I, whereas the relative risk reduction was similar.
conclusionIn individuals free of cardiovascular disease, the addition of troponin I to variables of established risk score improves prediction of cardiovascular death and cardiovascular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.